WASHINGTON — For the first time, federal health officials took aim at telehealth companies promoting unofficial versions of prescription drugs, part of the Trump administration's crackdown on pharmaceutical advertising.

The Food and Drug Administration posted more than 100 letters Tuesday to various drugmakers and online prescribing companies, including Hims & Hers, which built a multibillion dollar business centered around lower-cost versions of blockbuster weight-loss injections.

The FDA warned the company to remove "false and misleading" promotional statements from its website, including claims that its products contain "the same active ingredient" as FDA-approved drugs Wegovy and Ozempic.

The formulations cited by regulators are produced by specialty compounding pharmacies and aren'

See Full Page